Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil/memantine - Chong Kun Dang

Next Previous
Drug Profile

Donepezil/memantine - Chong Kun Dang

Alternative Names: CKD 355; CKD-355A; CKD-355B; D 797/D 324; D797/memantine HCl; Donepezil/memantine hydrochloride - Chong Kun Dang; Memantine hydrochloride/donepezil - Chong Kun Dang

Latest Information Update: 28 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Class Analgesics; Antidementias; Antiparkinsonians; Antispastics; Indans; Nootropics; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 28 May 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in South Korea (PO, Tablet)
  • 10 May 2019 Chong Kun Dang Pharmaceutical completes a phase I trial for Alzheimer's Disease (In volunteers) in South Korea (NCT03802162)
  • 25 Jan 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top